Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT06209112 |
| Other study ID # |
MoH/CSR/23/27624 |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
January 30, 2024 |
| Est. completion date |
July 31, 2024 |
Study information
| Verified date |
February 2024 |
| Source |
Royal Hospital, Oman |
| Contact |
Harihar V Hegde, MD |
| Phone |
+96898845606 |
| Email |
drharryhegde[@]yahoo.co.in |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
The goal of this observational study is to to evaluate a technique of initiating Sevoflurane
low-flow anesthesia which is simple, has a quick wash-in and minimises gas consumption
without compromising the safety when compared to conventional method of attaining low-flow
anesthesia using initial high flows.
Participants will explained about the procedure of induction of general anesthesia using
either one of the above two methods and written consent will be obtained prior to inclusion
in the study.
Description:
After obtaining the approval from the Institutional Ethics Committee of The Royal Hospital,
Muscat, we will register this prospective, randomised, descriptive study in an appropriate
online clinical trial registry. A written informed consent will be obtained from all the
patients. Forty-eight patients of either gender aged 18-65 years, with American Society of
Anesthesiologists (ASA) physical status of 1-2, undergoing elective surgery with the expected
duration more than 1 hour under general anaesthesia requiring endotracheal intubation will be
included. Pregnant women, smokers, patients with a body mass index (BMI) ≥30 kg/m2,
cardiac/pulmonary/renal or liver impairments, upper or lower respiratory infections within
the past 6 weeks and anticipated difficult airway will be excluded.
Age, gender, height and weight of the patients will be recorded. All the patients will follow
the standard fasting requirements and receive no sedative premedication. They will be
randomised before entering the operating room into one of the two groups, 'conventional
group' (Group C) and 'over-pressure group' (Group OP), using block randomisation technique
with varying block sizes. An appropriate intravenous cannula will be secured in the operating
room and Ringer's Lactate 500 ml will be started. The patients will receive standard
anaesthetic care and intra-operative monitoring with electrocardiogram, pulse oximeter
(SpO2), non-invasive blood pressure (NIBP) and capnography. Anaesthesia workstation (GE
Healthcare, Madison, WI, USA) which has an integrated anaesthetic gas analyser, displays
age-adjusted MAC according to the internal algorithm and returns sampled gas to the breathing
system will be used in this study. The breathing system will consist of a 2 litres reservoir
bag, disposable breathing circuit, heat-moisture exchanger and standard circle system with
Sodalime as the CO2 absorbent. The workstation will be tested to ensure no leak in the system
and vapourisers are calibrated.
Ideal Body Weight (IBW) of the patient will be calculated based on the following formula: IBW
(kg)=50 + 0.91 (height in cm - 152.4) for Men and 45.5 + 0.91 (height in cm - 152.4) for
Women. The ventilator will be preset in Pressure Control-Volume Guarantee (PCV-VG) mode with
a tidal volume of 8 ml/kg of IBW, respiratory rate=14 breaths/min, positive end-expiratory
pressure (PEEP)=5 cmH2O and an inspiratory:expiratory ratio of 1:2. The set minute volume
will be noted. The alarm for end-tidal Sevoflurane (FES) will be set at 2% to alert the
clinician.
Heart rate (HR), blood pressure (BP) and peripheral oxygen saturation will be recorded before
induction of anaesthesia, every minute until 5 min after induction and every 5 min intervals
thereafter. The FGF will be set at 6 L/min with 100% O2 during pre-oxygenation and manual
ventilation. Following pre-oxygenation for 3 min, general anaesthesia will be induced with
intravenous Fentanyl 2 μg/kg followed by Propofol 2 mg/kg administered over 30 seconds and
Rocuronium 1 mg/kg for neuromuscular blockade. Lungs will be ventilated manually and propofol
20 mg every minute will be administered until tracheal intubation. Tracheal intubation with
an appropriate size endotracheal tube (ETT) will be performed 90 seconds later, the cuff
inflated to 25-30 cmH2O using a cuff-pressure monitor device and ETT secured with an adhesive
tape. The correct ETT position will be confirmed by auscultation and square-wave capnography.
FGF will be paused during intubation and restarted after inflating the ETT cuff. The FGF
hereafter will consist of O2 and Air with a set FIO2=0.6. FGF and Sevoflurane vapouriser dial
(FVS) will be set as per the group allocation and mechanical ventilation will begin. The time
of opening of vapouriser will be considered Tzero.
Following will be the steps during wash-in for achieving LFA:
The 'conventional' group (Group C): FGF will be set to 6 L/min and the FVS 3% at Tzero. The
FGFwill be reduced to 0.5 L/min upon reaching FAS 2%. Hereafter, the FVS will be set to 4%
andmaintained till 15 min (T15) from Tzero.
The 'over-pressure' group (Group OP): FGF will be set to 0.5 L/min and FVS 8% at Tzero.
Subsequently, the FVS will be set to 4% upon reaching FAS 2% and maintained till 15 min (T15)
from Tzero.
The time of reaching FAS=2% will be noted in both the groups. The time taken in seconds from
Tzero to reach FAS 2% target concentration (Ttarget) will be calculated. Inspired
concentration of Sevoflurane (FIS), FAS, and age-adjusted MAC will be retrieved from the
automatically recorded 'trend' of parameters. FIS, FAS and age-adjusted MAC will be noted
every 30 sec. starting from Tzero, till T5 and every minute thereafter until T15.
Consumption of gases (Oxygen, Air and Sevoflurane) from the beginning until T15 will be
retrieved. Any reduction in mean BP >20% from the baseline will be treated with intravenous
Ephedrine 12 mg bolus and consumption of Ephedrine will be noted. Expired minute volume (MVE)
at Ttarget and T15 will be noted. The study period will end at T15 in both the groups.
Painting the surgical parts and draping will be permitted during the study period. Care will
be taken to avoid any activity which risks ETT disconnection during the study period.
Subsequent management of anaesthesia will be left to the discretion of the attending
Anaesthesiologist.
For both the groups, 'stability of Sevoflurane concentration', defined as FAS in the target
range of 1.6-2.4% during the time interval from Ttarget till T15 will be assessed. The
investigator will be allowed during this period to increase or decrease if needed the
vapouriser dial by 1% at a time every 2 min to keep the FES in the target range. The number
of times the vapouriser dial is adjusted will be noted. The system will be considered
'stable' if the FAS is maintained in the target range without the need for dial adjustment
and 'unstable' if vapouriser dial adjustment is needed at any time during this period.
Delivery of Oxygen will be monitored to ensure at least 300 ml/min and delivered FIO2 at
least 0.3 at all time. The investigator will be allowed to increase if needed the set FiO2 by
0.1 at a time every 2 min to keep the delivered FIO2>0.3. The number of times the set FIO2 is
adjusted will be noted. End-tidal carbon dioxide (ETCO2) will be maintained <40.
For both the groups, 'stability of Sevoflurane concentration', defined as FAS in the target
range of 1.6- 2.4% during the time interval from Ttarget till T15 will be assessed. The
investigator will be allowed during this period to increase or decrease if needed the
vapouriser dial by 1% at a time every 2 min to keep the FAS in the target range. The number
of times the vapouriser dial is adjusted will be noted.
The system will be considered 'stable' if the FAS is maintained in the target range without
the need for dial adjustment and 'unstable' if vapouriser dial adjustment is needed at any
time during this period.
Delivery of Oxygen will be monitored to ensure at least 300 ml/min and delivered FIO2 at
least 0.3 at all time. The investigator will be allowed to increase if needed the set FIO2 by
0.1 at a time every 2 min to keep the delivered FIO2>0.3. The number of times the set FIO2 is
adjusted will be noted. Endtidal carbon dioxide (ETCO2) will be maintained between 30 and 40.
The aim of the study is to assess during the wash-in phase of LFA the feasibility of the
method, stability of the system and consumption of gases. The primary outcome will be the
time required to achieve FAS 2%. Secondary outcomes will be the stability of the system
assessed by the number of times vapouriser dial and the set FIO2 adjusted, consumption of
gases and of ephedrine.
Statistical analysis Sample size is calculated based on a previous study8 which showed the
1-1-8 wash-in scheme with FGF=2L (O2 1 L + Air 1 L) and Sevoflurane dial at 8% yielded an FAS
of 2% at 2 ± 0.5 min. Hence, we assume that with our wash-in technique using FGF=0.5 L (O2 +
Air) and FVS 8% the time needed to reach FAS=2% will be around 8 min. To detect a difference
of 2 min (25%) with standard deviation (SD) of 2 using an alpha level of 0.05 and a power of
0.90 the sample size needed is 22 per group. For a possible 10% dropouts, it is decided to
include 24 patients per group.
Statistical analysis will be carried out using an appropriate statistical software. Data will
be presented as mean ± SD or median (range). Intergroup differences will be assessed for
significance using Student's t, Kruskal-Wallis, chi-squared or Fisher exact tests, as
appropriate. P < 0.05 will be considered statistically significant.
